drugset / Trial / NCT00379847

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

NCT00379847

Phase 3 Completed 251 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.

Timeline

Start
2004-02
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Conivaptan Small molecule

Indications

No indication recorded.